CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Portland, Oregon, United States and 40 other locations
CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...
Phase 2
Portland, Oregon, United States and 35 other locations
is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple...
Phase 1
Portland, Oregon, United States and 9 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Portland, Oregon, United States and 46 other locations
antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...
Phase 1
Portland, Oregon, United States and 25 other locations
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Ani...
Phase 2
Portland, Oregon, United States and 19 other locations
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...
Phase 3
Salem, Oregon, United States and 140 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
Portland, Oregon, United States and 278 other locations
the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple...
Phase 1, Phase 2
Portland, Oregon, United States and 39 other locations
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of ...
Phase 1
Portland, Oregon, United States and 12 other locations
Clinical trials
Research sites
Resources
Legal